Drug Approval | December 23, 2025
Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Subscribe To Our Newsletter & Stay Updated
